Drug intelligence / Profile preview

VIS513

Development stage: Phase 2
Lead developer: Serum Institute of India
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Dengushield (VIS513) is a recombinant monoclonal antibody developed by Serum Institute of India for the treatment and prevention of dengue virus infection. It is designed to neutralize all four serotypes of the dengue virus by targeting the envelope (E) protein, thereby inhibiting viral entry into host cells. The drug has undergone phase 1 clinical trials in healthy adults to assess safety and tolerability, with further development status unclear as of the latest updates. Its mechanism involves direct antiviral activity as a monoclonal antibody against dengue virus[1][2][4].

Brand names: Dengushield
Other names: dengue monoclonal antibody

Targets

DENV (Flavivirus antigens and proteins)

Beyond the preview

Go deeper on VIS513.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIS513.

Explore the full profile